Exhibit 10.12

[***] Certain information in this document has been  {E1 excluded}  pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely  {E2 cause}  competitive harm to the registrant if publicly  {E3 disclosed}  . Execution Version

COLLABORATION AGREEMENT

This COLLABORATION AGREEMENT (this "Agreement"), effective as of  September 13th, 2019  ("Effective  Date  "), is between Ginkgo Bioworks, Inc., a Delaware corporation with offices  located  at 27 Drydock Avenue, 8th floor, Boston, Massachusetts 02210 ("Ginkgo"), and Berkeley Lights, Inc., a Delaware corporation with offices  located  at 5858 Horton Street, Suite 320, Emeryville, California 94608 ("BLI"). Ginkgo and BLI may each be  {E4 referred}  to herein as a "Party" or, collectively, as the "Parties."

WHEREAS, BLI and Ginkgo are  {E5 committed}  to the goal of  {E6 developing}  and  {E7 deploying}  workflows on the Beacon Platform to  {E8 accelerate}  the engineering of microbial organisms and mammalian cell lines,  {E9 including}  by  {E6 developing}  new Workflows (as  {E11 defined}  below) for use on the Beacon Platform for the Parties' mutual benefit (the "Purpose"); and

WHEREAS, in furtherance of the Purpose, BLI and Ginkgo have  {E12 decided}  to  {E13 enter}  into this Agreement,  {E14 including}  mutually  {E15 agreed}  upon Workflow Development Plans, which  {E16 establish}  the terms by which Ginkgo and BLI will  {E17 work}  together to  {E18 bring}  their unique resources and experiences to  {E19 bear}  on the Purpose. NOW THEREFORE, in consideration of the above premises and the mutual covenants  {E20 contained}  herein, the Parties hereby  {E21 agree}  as  follows  : 1. DEFINITIONS

1.1 "Affected Party" has the meaning set forth Section 14.8 (Force Majeure). 1.2 "Affiliate" means with respect to a Party, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with that Party, for so long as such control exists. For purposes of this definition only, "control" and, with correlative meanings, the terms " controlled  by" and "under common control with" means: (a) in the case of Persons that are corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such corporate entity; and (b) in the case of Persons that are non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power to direct the management and policies of such non-corporate entity. 1.3 "Agreement" has the meaning set forth in the Preamble. 1.4 "[***]" means [***]. These  {E22 include}  [***]. For clarity, [***]  does  not  {E23 include}  [***]. 1.5 "Alliance Manager" has the meaning set forth in Section 3.7 (Alliance Managers). 1.6 "Antibody" means a soluble protein derived exclusively from an immunoglobulin protein that includes at least one hyper-variable antigen- binding region, including any fragment [***] of such protein, but, for clarity, excluding (i) [***] and (ii) [***]. 1.7 "Applicable Law" means federal, state, local, national and supra-national laws, statutes, rules and regulations, including any rules, regulations, regulatory guidelines or other requirements of Regulatory Authorities, major national securities exchanges or major securities listing organizations, that may be in effect from time to time during the  Term  and applicable to a particular activity or country hereunder. 1.8 "Arbitration Notice" has the meaning set forth in Section 14.5.2 (Dispute Resolution). 1.9 "Beacon Optofluidic Machine Improvement" means any improvement or modification to the Beacon Optofluidic Machine conceived, developed, generated or reduced to practice during the  Term  (a) solely by a Party, its Affiliates or Persons acting on behalf of such Party or (b) jointly by, on one hand, Ginkgo, its Affiliates or Persons acting on behalf of Ginkgo and, on the other hand, BLI, its Affiliates or Persons acting on behalf of BLI, in each case of clauses (a) and (b) of this Section 1.9 ("Beacon Optofluidic Machine Improvement" definition) through the conduct of activities under a Workflow Development Plan or otherwise arising out of the Parties' performance of activities under this Agreement. 1.10 "Beacon Optofluidic Machine" means (i) the machine with the Specifications set forth, as of the Effective  Date  , on Schedule 1.10 (Beacon Optofluidic Machine) and (ii) [***] and, with respect to (i)-(ii), any [***] of such machines, developed during the  Term  by BLI or its Affiliates that [***]. 1.11 "Beacon Platform" means, collectively, (a) the Beacon Optofluidic Machine, (b) the OptoSelect Chips, (c) Consumables related to the Beacon Optofluidic Machine or the OptoSelect Chips and (d) any Software. 1.12 "BLI" has the meaning set forth in the Preamble. 1.13 "BLI Background IP" means any Intellectual Property (a) Controlled by BLI or its Affiliates as of the Effective  Date  , (b) that comes into the Control of BLI after the Effective  Date  other than by means of this Agreement or the activities performed hereunder or (c) developed during the  Term  by BLI outside and independently of this Agreement. 1.14 "BLI Indemnitee" has the meaning set forth in Section 12.2 (Indemnification by Ginkgo). 1.15 "BLI Inventions" has the meaning set forth in Section 8.2.2 (Ownership of Materials and Data - BLI Inventions). 1.16 "BLI Proprietary Workflow" means any workflow on the Beacon Platform that was developed by or on behalf of BLI prior to the Effective  Date  or is developed during the  Term  in the conduct of activities outside and independent of this Agreement (including, for clarity, outside of any Workflow Development Plan), in each case whether solely by BLI or jointly by BLI and a Third Party. Page 2 of 85

1.17 "BLI Subcontractor" means a Person to whom BLI has subcontracted any of its activities under this Agreement pursuant to Section 2.7 (Subcontracting). 1.18 "BLI Terms and Conditions" means those terms and conditions set forth in Schedule 1.18 (BLI Terms and Conditions) and the Product Warranty, as such may be amended from time to time by BLI, [***]. 1.19 "Budget" means, with respect to a Workflow Development Plan, an itemized budget broken down on a [***] and high-level task-by-high-level task basis [***], that sets forth the following internal and out-of-pocket costs anticipated to be incurred in the conduct of activities under such Workflow Development Plan, to the extent applicable and mutually agreed upon by the Parties:

1.19.1 the FAS Support Costs for services  {E24 provided}  by any FAS under such Workflow Development Plan;

1.19.2 other FTE Costs for BLI's personnel in the conduct of activities under, or [***] under, such Workflow Development Plan,  {E25 including}  BLI personnel  {E26 conducting}  development of Software for the Workflow under such Workflow Development Plan;  {E27 provided}  that, with respect to the FTE Costs for BLI's personnel  {E28 providing}  [***] under a Workflow Development Plan, such FTE Costs shall not  {E29 exceed}  [***] percent ([***]%) of the total FTE Costs  {E30 charged}  to Ginkgo with respect to any invoice;

1.19.3 the out-of-pocket development ([***]) costs  {E31 paid}  by BLI to Third Parties to  {E32 purchase}   {E33 finished}  Consumables that are  {E34 developed}  and  {E35 designated}  as a deliverable under a Workflow Development Plan or raw materials necessary to  {E36 manufacture}  Consumables that are  {E34 developed}  and  {E35 designated}  as a deliverable under a Workflow Development Plan , in each case from such Third Parties for the Beacon Platform, subject to a [***] percent ([***]%) mark-up;

1.19.4 with respect to any then- existing  Consumables (i.e. not Consumables for which development or manufacture is ongoing as  {E39 described}  in Section 1.19.3), an amount equal to the number of units  {E40 used}  in the performance of the Workflow Development Plan,  {E41 multiplied}  by a price per unit of Consumables as set forth in Section 5.2.2(b) (Adjustments); and

1.19.5 other out-of-pocket costs  {E42 paid}  by BLI to  {E43 permitted}  Third Party subcontractors and vendors attributable to the development of the Workflow or Hardware under such Workflow Development Plan, [***]. 1.20 "Business Day" means any  day  , other than a  Saturday ,  Sunday  or  a day  on which commercial banks located in Boston, Massachusetts or San Francisco, California are authorized or required by Applicable Law or regulation or otherwise to close. Page 3 of 85

1.21 " Buy  -Down Amount" means, at any given time of a Buy-Down Election, an amount equal to:

1.21.1 if, at such time, [***], [***] ([***]%) of the difference between (a) the Full Purchase Target and (b) the sum of all the Development Purchases and Production Purchases  {E44 made}  or  {E45 incurred}  by Ginkgo;

1.21.2 if, at such time, [***], [***] percent ([***]%) of the difference between (a) the Full Purchase Target and (b) the sum of all the Development Purchases and Production Purchases  {E46 made}  or  {E47 incurred}  by Ginkgo as of such time;

1.21.3 if, at such time, [***], [***] percent ([***]%) of the difference between (a) the Full Purchase Target and (b) the sum of all the Development Purchases and Production Purchases  {E48 made}  or  {E49 incurred}  by Ginkgo as of such time; and

1.21.4 if, at such time, [***], [***]. For illustrative purposes only, Schedule 1.21 ( {E50 Buy}  -Down Examples)  {E51 sets}  forth a table  {E52 showing}  the  {E53 calculated}  Buy-Down Amounts  {E54 assuming}  [***] and [***]. 1.22 " Buy  -Down Election" has the meaning set forth in Section 7.3 (Buy-Down Election). 1.23 "Calendar Quarter" means the respective periods of three (3) consecutive calendar  months  ending on  March 31 ,  June 30 ,  September 30  and  December 31 ; provided that the first Calendar Quarter of the  Term  shall begin on the Effective  Date  and end on  the last day  of the then  current  Calendar Quarter and the last Calendar Quarter of the  Term  shall begin on the first  day  of such Calendar Quarter and end on  the last day  of the  Term  . 1.24 "[***]" means [***] that [***], including [***], by [***], whose [***]. 1.25 "[***]" means the offering or performance of any services using the Beacon Platform, [***], to [***]:

1.25.1 [***];

1.25.2 [***]; or

1.25.3 [***];

{E55 provided}  that in no event shall [***]  {E56 include}  the use of the Beacon Platform to (i) [***] or (ii) [***] but, for clarity, are not in any manner or form  {E57 used}  as  {E58 described}  in Sections 1.25.1, 1.25.2 or 1.25.3 above. 1.26 "Change in Control" means, with respect to a Person, (a) the acquisition, directly or indirectly, by a Person or "group" (whether in a single transaction or multiple transactions) of fifty percent (50%) or more of the voting power of such Person or of beneficial ownership of (or the right to acquire such beneficial ownership) fifty percent (50%) or more of the outstanding Page 4 of 85

equity or convertible securities of such Person ( {E59 including}  by tender offer or exchange offer); (b) any merger, consolidation, share exchange, business combination, recapitalization or similar corporate transaction  {E60 involving}  such Person (whether or not  {E61 including}  one or more wholly  {E62 owned}  subsidiaries of such Person) or (c) such Person  {E63 sells}  or transfers to any Third Party, in one or more related transactions, properties or assets  {E64 representing}  all or substantially all of such Person's consolidated total assets to which this Agreement  {E65 relates}  . 1.27 "Claims" is  {E66 defined}  in Section 12.1 (Indemnification by BLI). 1.28 "Clinical Trial" means a human clinical study conducted on sufficient numbers of human subjects that is designed to (a) establish that a product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with the product in the dosage range to be prescribed or (c) support Regulatory Approval of such product or label expansion of such product. Without  {E67 limiting}  the foregoing, Clinical Trial  {E68 includes}  any Phase II Clinical Trial or Phase III Clinical Trial  {E69 conducted}  by or on behalf of one or both Parties in connection with this Agreement. 1.29 "Collaboration Data" has the meaning set forth in Section 8.5.1 (Disclosure). 1.30 "Collaboration Intellectual Property" means [***], that is conceived, developed, generated or reduced to practice during the  Term  (a) solely by a Party, its Affiliates or Persons acting on behalf of such Party or (b) jointly by, on one hand, Ginkgo, its Affiliates or Persons acting on behalf of Ginkgo and, on the other hand, BLI, its Affiliates or Persons acting on behalf of BLI, in each case of clauses (a) and (b) of this Section 1.30 ("Collaboration Intellectual Property" definition) through the conduct of activities under this Agreement. 1.31 "Collaboration Workflow" means any Workflow on the Beacon Platform that [***] and is (a) developed jointly by the Parties (or on their behalf) or (b) developed solely by BLI (or on behalf of BLI) for Ginkgo, in each case of clause (a) and (b) of this Section 1.31 ("Collaboration Workflow" definition), pursuant to a Workflow Development Plan. For the avoidance of doubt, Collaboration Workflows shall not  {E70 include}  [***]. 1.32 "Commercial Services" means any [***] activities conducted by Ginkgo or any sublicensee under the rights granted to Ginkgo by BLI in Section 9.1.1 (Scope of Grants) in the Licensed Field (a) under an agreement or arrangement of Ginkgo or any such sublicensee with a Third Party or (b) for [***] that [***] by Ginkgo, an Affiliate or a Third Party; provided that, notwithstanding the foregoing, with respect to Third Parties, Workflows may only be [***] by Ginkgo permitted (under Section 9.1 (Grants to Ginkgo)) sublicensees, but no other Third Parties. 1.33 " Completed  Workflow" means any Key Collaboration Workflow that the JRC or the Expert Panel, as applicable, determines has been Substantially Completed. 1.34 "Confidential Information" has the meaning set forth in Section 10.1 (Confidential Information). Page 5 of 85

1.35 "Conforming Product" means, with respect to a Beacon Optofluidic Machine or Consumable delivered by BLI to Ginkgo under this Agreement, that such Beacon Optofluidic Machine or Consumable meets the Product Warranty at the time of delivery. 1.36 "Consumables" means those certain OptoSelect Chips and reagents set forth on Schedule 1.36 (Consumables) or that, during the  Term  , [***] for the use of the Beacon Platform and are sold by BLI. 1.37 "Contract Year" means (a) with respect to the first Contract Year, the period of time commencing on the Effective  Date  and ending on  September 30, 2020  and (b) with respect to each subsequent Contract Year, commencing on  October 1  of such Contract Year and continuing for a period of twelve (12) consecutive calendar  months  ; provided that the last Contract Year of the  Term  shall end on  the last day  of the  Term  .



#COLOR:E6=hsl(50, 100%, 80%)
#COLOR:E34=hsl(0, 100%, 80%)
#COLOR:E35=hsl(25, 100%, 80%)

#TOKENIZATION-TYPE:1

